PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'INSERM, EFS BFC, UMR1098, RIGHT, University of Burgundy Franche-Comte, Besançon, France.\', \'Department of Pharmacy, University Hospital of Besançon, Besançon, France.\', \'INSERM CIC1431, Clinical Investigation Center in Biotherapy, Biomonitoring Plateform, Besançon, France.\', \'Department of Medical Oncology, Biotechnology and Immune-Oncology Platforme, University Hospital of Besançon, Besançon, France.\', \'Établissement Français du Sang Bourgogne Franche-Comté, Besançon, France.\', \'Établissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France.\', \'SAINBIOSE, INSERM, U1059, University of Lyon, Saint-Etienne, France.\', \'Établissement Français du Sang, La Plaine St-Denis, France.\', \'UMR \'Unité des Virus Emergents\', Aix-Marseille Université - IRD 190 - INSERM 1207 - IRBA - EFS - IHU Méditerranée Infection, Marseille, France.\', \'Department of Hematology, Necker Hospital, Paris, France.\', \'Institut Imagine, INSERM UMR1183, Paris University, Paris, France.\', \'Infectious Diseases Department, Saint-Antoine Hospital, AP-HP, Paris, France.\', \'INSERM IPLESP, AP-HP, Sorbonne University, Paris, France.\', \'Department of Medical Oncology, University Hospital of Besançon, Besançon, France.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.3389/fpubh.2022.816848
?:doi
?:hasPublicationType
?:journal
  • Frontiers in public health
is ?:pmid of
?:pmid
?:pmid
  • 35372242
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.769
?:rankingScore_hIndex
  • 23
is ?:relation_isRelatedTo_publication of
?:title
  • The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all